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Abstract: 
Background and Aims: The systemic inflammatory response is associated with the loss of lean tissue, anorexia, weakness, fatigue and reduced survival in patients with advanced cancer and therefore is important in the definition of cancer cachexia. The aim of the present study was to carry out a direct comparison of the prognostic value of Eastern Cooperative Oncology Group Performance Status (ECOG-PS), modified Glasgow Prognostic Score (mGPS) and Body Mass Index/Weight Loss Grade (BMI/WL grade) in patients with advanced cancer. 
Method: All data were collected prospectively across 18 sites in the UK and Ireland. Patient’s age, sex, ECOG-PS, mGPS and BMI/WL grade were recorded, as were details of underlying disease including metastases. Survival data were analysed using univariate and multivariate Cox regression.  
Results: A total of 730 patients were assessed. The majority of patients were male (53%), over 65 years of age (56%), had an ECOG-PS>0/1 (56%), mGPS≥1 (56%), BMI≥25 (51%), <2.5% weight loss (57%) and had metastatic disease (86%).  On multivariate cox regression analysis ECOG-PS (HR 1.61 95%CI 1.42-1.83, p<0.001), mGPS (HR 1.53, 95%CI 1.39-1.69, p<0.001) and BMI/WL grade (HR 1.41, 95%CI 1.25-1.60, p<0.001) remained independently associated with overall survival. In patients with a BMI/WL grade 0/1 both ECOG and mGPS remained independently associated with overall survival.
Conclusion: The ECOG/mGPS framework may form the basis of risk stratification of survival in patients with advanced cancer. 


Statement of Significance: 
This study shows that the ECOG/mGPS framework had prognostic value where BMI/WL was normal. This would suggest that the ECOG/mGPS framework may form the basis of risk stratification of survival and provide diagnostic criteria for cachexia in patients with advanced cancer. Furthermore, it would redirect clinical efforts to treat cachexia.   

 
Introduction
	
The recognition of the poor prognosis associated with the syndrome of cachexia dates back to ancient Greece. These observations remain valid today as in patients with advanced cancer, progressive involuntary loss of body weight and lean tissue, anorexia, weakness and fatigue (cancer cachexia) are associated with poor survival ADDIN EN.CITE [1].  Despite the clinical recognition of the syndrome of cancer cachexia, performance status remains the most routinely assessed clinical measure on which to base likely patient outcome to treatment and prognosis  ADDIN EN.CITE [2].  
There is now consistent evidence that the presence of a systemic inflammatory response, as evidenced by the modified Glasgow Prognostic Score (mGPS) is associated with the loss of lean tissue, anorexia, weakness and fatigue and poor survival in patients with advanced cancer  ADDIN EN.CITE [3, 4].  Moreover, the mGPS, in combination with ECOG-PS, has been shown to effectively stratify the above measures of cachexia  ADDIN EN.CITE [2, 5].
As a direct extension of the consensus statement of Fearon and coworkers, Martin and colleagues (2015), in a large cohort study of more than 8,000 patients with advanced cancer proposed that cachexia should be graded according to the concurrent Body Mass Index (BMI) and the degree of weight loss (WL)  ADDIN EN.CITE [6].  They showed that the BMI/WL grade had independent prognostic value and effectively stratified survival.  More recently, this grading system has been reported to be associated with quality of life [7]. 
Therefore, while ECOG-PS, mGPS and BMI/WL grade are all associated with symptom burden and have valid prognostic value, to date, there has been no direct comparison of their prognostic value in patients with advanced cancer.  Such a comparison may inform clinical practice as to which factors are associated with reduced survival and in turn inform the assessment and treatment of cancer cachexia.  Therefore, the aim of the present study was to compare the prognostic value of ECOG-PS, mGPS and BMI/WL in a prospective cohort of patients with advanced cancer.The recognition of the poor prognosis associated with the syndrome of cachexia dates back to ancient Greece. These observations remain valid today as in patients with advanced cancer, progressive involuntary loss of body weight and lean tissue, anorexia, weakness and fatigue (cancer cachexia) are associated with poor survival ADDIN EN.CITE [1].  Despite the clinical recognition of the syndrome of cancer cachexia, performance status remains the most routinely assessed clinical measure on which to base likely patient outcome to treatment and prognosis  ADDIN EN.CITE [2].  

There is now consistent evidence that the presence of a systemic inflammatory response, as evidenced by the modified Glasgow Prognostic Score (mGPS) is associated with the loss of lean tissue, anorexia, weakness and fatigue and poor survival in patients with advanced cancer  ADDIN EN.CITE [3, 4].  Moreover, the mGPS, in combination with ECOG-PS, has been shown to effectively stratify the above measures of cachexia  ADDIN EN.CITE [2, 5].
As a direct extension of the consensus statement of Fearon and coworkers, Martin and colleagues (2015), in a large cohort study of more than 11,000 patients with advanced cancer proposed that cachexia should be graded according to the concurrent Body Mass Index (BMI) and the degree of weight loss (WL)  ADDIN EN.CITE [6].  They showed that the BMI/WL grade had independent prognostic value and effectively stratified survival.  More recently, this grading system has been reported to be associated with quality of life [7]. 
Therefore, while ECOG-PS, mGPS and BMI/WL grade are all associated with symptom burden and have valid prognostic value, to date, there has been no direct comparison of their prognostic value in patients with advanced cancer.  Such a comparison may inform clinical practice as to which factors are associated with reduced survival and in turn inform the assessment and treatment of cancer cachexia.  Therefore, the aim of the present study was to carry out such a comparison in a prospective cohort of patients with advanced cancer. 


Patients and Methods
Patients:
An international database of patients with advanced cancer was analysed. All data were collected prospectively across 18 sites in the UK and Ireland (cancer centres, hospitals, and specialist palliative care units) over a five-year period (2011-2016). Eligible patients met the following criteria: >18 years of age; advanced cancer (defined as metastatic cancer [histological, cytological or radiological evidence], locally advanced or receiving anti-cancer therapy with palliative intent); able to complete study questionnaires; provide a venous blood sample and with a recorded ECOG-PS. Patients were excluded if they had breast or prostate carcinoma with only bone metastases as their survival times could be many years and therefore an argument could be made that they did not in fact have advanced cancer. Patients who were undergoing active anti-cancer therapy or not, on both an inpatient and outpatient basis were included. The study had ethics committee approval in both the UK and Ireland (UK-12/SS/0181 and Ireland EMC 4(g) 2015) and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. The study adhered to the STROBE guidelines for cohort studies.
Individual centres were opened at staggered time points. Within each centre, patients who fulfilled the eligibility criteria were invited to participate and consented on a sequential basis therefore reducing selection bias (Table 1). All assessments, including blood sampling, were performed on the day of consent.”
An international database of patients with advanced cancer was analysed. All data were collected prospectively across 18 sites in the UK and Ireland (cancer centres, hospitals, and specialist palliative care units) over a five-year period (2011-2016). Eligible patients met the following criteria: >18 years of age; advanced cancer (defined as metastatic cancer [histological, cytological or radiological evidence], locally advanced or receiving anti-cancer therapy with palliative intent); able to complete study questionnaires; provide a venous blood sample and with a recorded ECOG-PS. Patients were excluded if they had breast or prostate carcinoma with only bone metastases as their survival times could be many years and therefore an argument could be made that they did not in fact have advanced cancer. Patients who were undergoing active anti-cancer therapy or not, on both an inpatient and outpatient basis were included. The study had ethics committee approval in both the UK and Ireland (UK-12/SS/0181 and Ireland EMC 4(g) 2015) and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. The study adhered to the STROBE guidelines for cohort studies.
Individual centres were opened at staggered time points. Within each centre (summary Table ?), patients who fulfilled the eligibility criteria were invited to participate and consented on a sequential basis therefore reducing selection bias. All assessments, including blood sampling, were performed on the day of consent
Prognostic markers
Clinicopathological data including the patient’s age, sex, ECOG-PS, mGPS, BMI/WL grade, underlying primary disease, and the presence of metastasis were recorded ADDIN EN.CITE [2, 7, 8].  
Bio-markers: C-reactive protein (CRP) and albumin combined in the mGPS.  An autoanalyzer was used to measure serum CRP (mg/L) and albumin (g/L) concentrations (Architect; Abbot Diagnostics, Maidenhead, UK).  The mGPS and BMI/WL grade was derived as previously described. ADDIN EN.CITE [7, 9] 
Statistical analysis:
Categorical variables were analysed using χ2 test for linear-by-linear association, or χ2 test for 2 by 2 tables.  Patients were followed prospectively until the date of censoring (11/06/2018) or date of death from any cause (if present). Survival time was calculated from the date of recruitment to the date of death or censoring, whichever came first.  Three month survival rate was examined since patients who have less than 3 month survival are considered to have refractory disease (cachexia) and allowed comparison with other studies [2, 5, 6]. Patients were followed prospectively until the date of censoring (11/06/2018) or date of death from any cause (if present). Survival time was calculated from the date of recruitment to the date of death or censoring, whichever came first.  Three month survival rate was examined since patients who have less than 3 month survival are considered to have refractory disease (cachexia) and allowed comparison with other studies [2,5,6].  Survival data were analysed using univariate and multivariate Cox regression.  In addition to significant variables of interest on univariate analysis the predefined variables age, sex and cancer location were entered into a backward conditional multivariate model. Given the central prognostic role of performance status in patients with advanced cancer and the increased integration of oncology and palliative care ECOG-PS was taken as the primary stratification factor ADDIN EN.CITE [10].Given the central prognostic role of performance status in patients with advanced cancer and the increased integration of oncology and palliative care [Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, Brunelli C, Caraceni A, Cervantes A, Currow DC, Deliens L, Fallon M, Gómez-Batiste X, Grotmol KS, Hannon B, Haugen DF, Higginson IJ, Hjermstad MJ, Hui D, Jordan K, Kurita GP, Larkin PJ, Miccinesi G, Nauck F, Pribakovic R, Rodin G, Sjøgren P, Stone P, Zimmermann C, Lundeby T. Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol. 2018 Nov;19(11):e588-e653] ECOG-PS was taken as the primary stratification factor.    Cox Regression analysis was carried out for ECOG-PS, mGPS and BMI/WL grade to establish proportional Hazard Ratios. 
Two tailed p values <0.05 were considered statistically significant.  Statistical analysis was performed using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA).


Results
A total of 730 patients (390 males, 340 females) met the eligibility criteria. The clinicopathological characteristics of the study population is shown in Table 21. The majority of patients were over 65 years of age (55.8%), had an ECOG-PS>0/1 (56.0%), mGPS>0 (55.5%), BMI/ weight loss grade 0/1 (55%) and had metastatic disease (85.8%).The majority of patients were over 65 years of age (55.8%), had an ECOG-PS>0/1 (56.0%), mGPS>0 (55.5%), BMI/ weight loss grade 0/1 (55%) and had metastatic disease (85.8%). The majority of tumours were gastrointestinal (42.9%) and lung (28.2%) cancers.  In those patients with tumours other than these the tumour types included Neurological 7 (1%), Urology 46 (6%), Gynaecological 33 (5%), Melanoma 28 (4%), Haematological 26 (4%), Breast 47 (6%), Unknown Primary 10 (1%), Others 14 (2%). The majority of tumours were gastrointestinal (42.9%) and lung (28.2%) cancers.  In those patients with tumours other than these the tumour types included Neurological 7 (1%), Urology 46 (6%), Gynaecological 33 (5%), Melanoma 28 (4%), Haematological 26 (4%), Breast 47 (6%), Unknown Primary 10 (1%), Others 14 (2%).The median overall survival (OS) for the entire cohort was 7.3 months (95% CI: 1.0-73.63 months). At the time of censoring, 182 patients (39.5%) were still alive. Median follow up time for these patients was 6.6 months (95% CI: 5.8-7.1 months). 
The relationship between ECOG-PS, mGPS and BMI/WL grade and overall survival in patients with advanced cancer is shown in Table 32 and Figures 1-3. On multivariate cox regression analysis ECOG-PS (HR 1.61 95%CI 1.42-1.83, p<0.001), mGPS (HR 1.53, 95%CI 1.39-1.69, p<0.001) and BMI/WL grade (HR 1.41, 95%CI 1.25-1.60, p<0.001) remained independently associated with overall survival. 
In patients with an ECOG-PS 0/1 the relationship between mGPS and BMI/WL grade and overall survival in patients with advanced cancer is shown in Table 32b. On multivariate cox regression analysis mGPS (HR 1.50, 95%CI 1.32-1.72, p<0.001) and BMI/WL Grade (HR 1.29, 95%CI 1.06-1.56, p=0.009) remained independently associated with overall survival. 
In patients with an ECOG-PS 2 the relationship between mGPS and BMI/WL grade and overall survival in patients with advanced cancer is shown in Table 32c. On multivariate cox regression analysis mGPS (HR 1.56, 95%CI 1.32-1.86, p<0.001) and BMI/WL Grade (HR 1.46, 95%CI 1.19-1.80, p<0.001) remained independently associated with overall survival. 
In patients with an ECOG-PS 3/4 the relationship between mGPS and BMI/WL grade and overall survival in patients with advanced cancer is shown in Table 32d. On multivariate cox regression analysis mGPS (HR 1.55, 95%CI 1.12-2.15, p=0.009) and BMI/WL grade (HR 1.53, 95%CI 1.11-2.12, p=0.010) remained independently associated with overall survival. 
The relationship between ECOG-PS, mGPS and 3-month survival is shown in Table 34. In patients with an ECOG-PS of 0/1 there was a significant association between mGPS and 3-months survival (p<0.001). In patients with an ECOG-PS of 2 there was a significant association between mGPS and 3-months survival (p<0.001). In patients with an ECOG-PS of 3/4 there was a non-significant association between mGPS and 3-months survival (p=0.102). In patients with an ECOG-PS of 0-4 there was a significant association between mGPS and 3-months survival (p<0.001). 
 In patients with an mGPS of 0 there was a significant association between ECOG-PS and 3-months survival (p<0.001). In patients with an mGPS of 1 there was a significant association between ECOG-PS and 3-months survival (p=0.021). In patients with an mGPS of 2 there was a significant association between ECOG-PS and 3-months survival (p<0.001). In patients with an mGPS of 0-2 there was a significant association between ECOG-PS and 3-months survival (p<0.001).       
The relationship between ECOG-PS, mGPS and 3-month survival in patients with a BMI/WL grade 0/1 is shown in Table 45. In patients with an ECOG-PS of 0/1 there was a significant association between mGPS and 3-months survival (p=0.001). In patients with an ECOG-PS of 2 there was a trend to a significant association between mGPS and 3-months survival (p=0.085). In patients with an ECOG-PS of 3/4 there was a non-significant association between mGPS and 3-months survival (p=0.741). In patients with an ECOG-PS of 0-4 there was a significant association between mGPS and 3-months survival (p<0.001). 
 In patients with an mGPS of 0 there was a significant association between ECOG-PS and 3-months survival (p=0.001). In patients with an mGPS of 1 there was a non-significant association between ECOG-PS and 3-months survival (p=0.343). In patients with an mGPS of 2 there was a significant association between ECOG-PS and 3-months survival (p=0.003). In patients with an mGPS of 0-2 there was a significant association between ECOG-PS and 3-months survival (p<0.001).       


Discussion
The results of the present study show that, in a prospective cohort of patients with advanced cancer and a median survival of 7 months, the majority of patients  had a good performance status, low BMI/WL grade (normal BMI, minimal weight loss) and had evidence of a systemic inflammatory response.The results of the present study show that, in a prospective cohort of patients with advanced cancer and a median survival of 7 months, the majority of patients had a good performance status, low BMI/WL grade (normal BMI, minimal weight loss) and had evidence of a systemic inflammatory response. Although ECOG-PS, mGPS and BMI/WL grade all effectively stratified overall survival when adjusted for age, sex and cancer location, both ECOG-PS and mGPS also stratified patient survival in those patients with a low BMI/WL grade. Therefore, the combination of ECOG-PS/ mGPS/ BMI/WL grade consistently stratifies survival in patients with advanced cancer  ADDIN EN.CITE [2, 5, 11]. 
The results of the present study are consistent with the work of Martin and colleagues who examined the relationship between weight loss grade, performance status and the GPS in more than 2,500 patients with advanced cancer and a median survival of 7.6 months [12].  Unfortunately, to date this data has only been published in abstract form.  Nevertheless, the tabulated data presented in abstract are consistent with the present analysis and their conclusions that eseveare“a combination of BMI/ WL grades, PS and GPS consistently stratifies advanced cancer patients into very different survival groups, and could be considered as diagnostic criteria for cachexia” have been confirmed and extended in the present study [12].  For example, in the present study, in Table 5, the numbers of patients with ECOG-PS 3-4 cohort (BMI/WL grade 0/1) were relatively small (n=33) and the mGPS did not significant stratify survival.  However, in the study of Martin and colleagues [11] in a larger cohort (n=2,656) the numbers of patients with ECOG-PS 3-4 was 96 and mGPS significantly stratified survival.  Therefore, the ECOG-PS 3-4 subsample in the present study was likely to be underpowered.   It remains to be whether BMI/WL grade as an indicator of nutritional risk is superior to routine clinical screening tools such as MUST  ADDIN EN.CITE [13].  Moreover, such work is the basis of the rationalisation of the multiple tools developed to identify clinically important cachexia, sarcopenia and malnutrition.The results of the present study are consistent with the work of Martin and colleagues who examined the relationship between weight loss grade, performance status and the GPS in more than 2,500 patients with advanced cancer and a median survival of 7.6 months [12].  Unfortunately, to date this data has only been published in abstract form.  Nevertheless, the tabulated data in abstract is consistent with the present analysis and their conclusions that “a combination of BMI/ WL grades, PS and GPS consistently stratifies advanced cancer patients into very different survival groups, and could be considered as diagnostic criteria for cachexia” have been confirmed and extended in the present study [12].  For example, in the present study, in Table 4, the numbers of patients with ECOG-PS 3-4 cohort (BMI/WL grade 0/1) were relatively small (n=33) and the mGPS did not significant stratify survival.  However, in the study Martin and colleagues [11] in a larger cohort (n=2,656) the numbers of patients with ECOG-PS 3-4 was 96 and mGPS significantly stratified survival.  Therefore, the ECOG-PS 3-4 subsample in the present study was likely to be underpowered.   It remains to be whether BMI/WL grade as an indicator of nutritional risk is superior to routine clinical screening tools such as MUST [Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, Erickson N, Laviano A, Lisanti MP, Lobo DN, McMillan DC, Muscaritoli M, Ockenga J, Pirlich M, Strasser F, de van der Schueren M, Van Gossum A, Vaupel P, Weimann A. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017 Oct;36(5):1187-1196].  Moreover, such work is the basis of the rationalisation of the multiple tools developed to identify clinically important cachexia, sarcopenia and malnutrition.
	The results of the present study indicate the importance of the systemic inflammatory response not only as a prognostic factor but also to inform the nutritional and functional decline associated with advanced cancer.  Indeed, in those patients who had both a good performance status and good BMI/WL grade (no obvious functional decline or weight loss), the mGPS effectively stratified median survival between 11.4 months and 7.5 months.  Furthermore, in those patients, 42% had an elevated mGPS.  One interpretation of the findings is that obvious weight loss in patients with advanced cancer is a later event than functional decline, and that functional decline is a later event than the development of a systemic inflammatory response [14].  Therefore, it may be that the mGPS should form the basis of stratification of likely survival in patients with advanced cancer.  Indeed, the prognostic value of the mGPS has been extensively validated in early stage disease [15]. Moreover, some workers have proposed that in “the more aggressive tumour types (e.g. pancreas and lung), the future of patients with elevated mGPS scores is so grim that they should be given precachexia status and offered multimodal therapy which may delay the onset of cachexia and/or death [16].  Also, Morley (2019) commented that although the cachexia score (CASCO) has been identified “as the best screening test available for cachexia, a quicker screen that may be equally effective is the Glasgow Prognostic Score” [17].  Irrespective, greater prominence should be given to the assessment of the systemic inflammatory response (as evidenced by the mGPS) in patients with advanced cancer  ADDIN EN.CITE [3].  Moreover, the systemic inflammatory response may be considered a cardinal feature of the syndrome of cancer cachexia  ADDIN EN.CITE [18, 19]. If this proves to be the case then the systemic inflammatory response will become an important therapeutic target for cancer cachexia in the coming years  ADDIN EN.CITE [20]. Indeed, targeting the inflammatory response to treat cancer cachexia has been proposed as a therapy with clinical trials now underway  ADDIN EN.CITE [21, 22]. Trials have examined this in the past but importantly patients were not entered into these trials on the basis of their systemic inflammatory response. 
  The present study had a number of limitations. The majority of patients were undergoing palliative care. As a result, it could be assumed that there had a high symptom burden which has been shown to be associated with worse outcomes. Furthermore, despite recruitment occurring across 18 sites, the patient cohort may not be completely representative of patients with advanced cancer. However, they were well defined in terms of the components of know and validated prognostic scores which will allow for direct comparison with other populations in future studies. Finally, the method of patient recruitment/sampling strategy was opportunistic. However, the heterogeneity of the primary cancer types suggests that the recruitment process while being opportunistic was robust.  
In summary, while ECOG-PS, mGPS and BMI/WL grade are all valid prognostic scores and may form the basis of future risk stratification of survival in patients with advanced cancer. 
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Table 1. Summary table of recruitment centres including patient numbers 
Centres	Overall numbers Recruited	Numbers Excluded	Numbers included in Final Analysis 
Abersy 	31 (3.0)	2 (0.7)	29 (4.0)
Beatson Glasgow 	96 (9.3)	1 (0.3)	95 (13.0)
Coventry	29 (2.8)	3 (1.0)	26 (3.6)
CUH 	166 (16.2)	155 (52.2)	11 (1.5)
Denbigh 	54 (5.3)	13 (4.4)	41 (5.6)
Eastwood	26 (2.5)	3 (1.0)	23 (23.2)
Edinburgh 	15 (1.5)	3 (1.0)	12 (1.6)
Gwyned	22 (2.1)	0 (0.0)	22 (3.0)
Hayward	34 (3.3)	2 (0.7)	32 (4.4)
MUH	383 (37.3)	59 (19.9)	324 (44.4)
Nighting	27 (2.6)	6 (2.0)	21 (2.9)
Port Talbert	2 (0.2)	1 (0.3)	1 (0.1)
PPWH	17 (1.7)	2 (0.7)	15 (2.1)
Scar	4 (0.4)	3 (1.0)	1 (0.1)
St. Andrews	9 (0.9)	1 (0.3)	8 (1.1)
St Gem	70 (6.8)	33 (11.1)	37 (5.1)
Strathclyde	5 (0.5)	1 (0.3)	4 (0.5)
Wrexham 	37 (3.6)	9 (3.0)	28 (3.8)
Total	1027	297	730



Table 21. Clinicopathological characteristics of patients with advanced cancer (n=730)
Characteristic	
	n=730 (%)
	Clinico-pathological	
Age	<65	323 (44.2)
	65 - 74	225 (30.8)
	>74	182 (24.9)
Sex	Male	390 (53.4)
	Female	340 (46.6)
Cancer Location 	Lung 	206 (28.2)
	GI	313 (42.9)
	Other	211 (28.9)
Metastatic Disease	No	104 (14.2)
	Yes	626 (85.8)
	Previous Ant-Cancer Therapy 	
Chemotherapy	No	148 (20.3)
	Yes	582 (79.7)
Radiotherapy	No	572 (78.4)
	Yes	158 (21.6)
Hormones	No	678 (92.9)
	Yes	52 (7.1)
	Performance status	
ECOG-PS˥	0/1	409 (56.0)
	2	240 (32.9)
	3/4	81 (11.1)
	Systemic Inflammation 	
mGPS˦	0	325 (44.5)
	1	111 (15.2)
	2	294 (40.3)
	Body composition	
BMI˧	≤20.0 kg/m2	99 (13.6)
	20-21.9 kg/m2	92 (12.6)
	22-24.9 kg/m2	174 (23.4)
	25-27.9 kg/m2	156 (21.4)
	≥28.0 kg/m2	209 (28.6)
% Weight Loss	<2.5	415 (56.8)
	≥2.5	315 (43.2)
BMI/WL grade˨	0/1	404 (55.3)
	2/3	241 (33.0)
	4	85 (11.6)
˥ ECOG-P: Eastern Cooperative Oncology Group Performance Status, ˦ mGPS: modified Glasgow Prognostic Score, ˧ BMI: ˨Body Mass Index, BMI/WL grade: Body Mass Index/Weight Loss Grade


Table 23. The relationship between ECOG, mGPS and BMI/WL grade and overall survival in patients with advanced cancer.
						
Characteristics 	Univariate	p-value 	Multivariate	p-value	Multivariate Adjusted for Age, Sex and Cancer Location	p-value
Table 23a ECOG-PS  0/1-4 (n=730)						
ECOG-PS˥	1.85 (1.63-2.09)	<0.001	1.61 (1.42-1.83)	<0.001	1.64 (1.44-1.86)	<0.001
mGPS˦	1.63 (1.48-1.80)	<0.001	1.53 (1.39-1.69)	<0.001	1.49 (1.35-1.64)	<0.001
BMI/WL grade˨	1.48 (1.30-1.67)	<0.001	1.41 (1.25-1.60)	<0.001	1.39 (1.23-1.58)	<0.001
						
Table 32b ECOG-PS  0/1 (n=409)		 				
mGPS˦	1.51 (1.32-1.72)	<0.001	1.50 (1.32-1.72)	<0.001	1.44 (1.26-1.65)	<0.001
BMI/WL grade˨	1.29 (1.07-1.56)	0.007	1.29 (1.06-1.56)	0.009	1.25 (1.03-1.51)	0.024
						
Table 23b ECOG-PS 2 (n=240)						
mGPS˦	1.59 (1.34-1.89)	<0.001	1.56 (1.32-1.86)	<0.001	1.53 (1.28-1.82)	<0.001
BMI/WL grade˨	1.50 (1.22-1.84)	<0.001	1.46 (1.19-1.80)	<0.001	1.43 (1.16-1.76)	0.001
						
Table 32c ECOG-PS 3-4 (n=81)						
mGPS˦	1.42 (1.04-1.95)	0.029	1.55 (1.12-2.15)	0.009	1.54 (1.11-2.14)	0.009
BMI/WL grade˨	1.37 (1.02-1.84)	0.039	1.53 (1.11-2.12)	0.010	1.58 (1.15-2.19)	0.005
˥ ECOG-P: Eastern Cooperative Oncology Group Performance Status, ˦ mGPS: modified Glasgow Prognostic Score, ˧ BMI: ˨Body Mass Index, BMI/WL grade: Body Mass Index/Weight Loss Grade. Statiscial analysis was with univariate and multivariate Cox regression analysis. 



Table 43. The relationship between the ECOG-PS, mGPS and 3 month survival rate in patients with advanced cancer (n=730)
ECOG-PS˥		mGPS˦=0	mGPS˦=1	mGPS˦=2	mGPS˦ 0-2	
		n (%)	n (%)	n (%)	n (%)	P-value
0-1	n	226	56	127	409	
	Survival Rate at 3 months 	218 (96.5%)	46 (82.1%)	105 (82.7%)	369 (90.26%)	<0.001
	Median Survival 	10.9	7.0	7.0	9.1	
	95% CI	9.2-12.3	5.3-10.2	5.7-8.9	8.0-10.0	
2	n	87	42	111	240	
	Survival Rate at 3 months 	76 (87.4%)	28 (66.7%)	62 (55.9%)	166 (69.2%)	<0.001
	Median Survival 	7.3	5.0	3.5	5.2	
	95% CI	6.1-9.8	3.1-6.6	2.6-4.8	4.6-5.7	
3-4	n	12	13	56	81	
	Survival Rate at 3 months 	8 (66.7%)	6 (46.2%)	19 (33.9%)	33 (40.7%)	0.102
	Median Survival 	5.9	2.6	1.9	2.5	
	95% CI	2.5-14.2	0.6-4.5	1.2-2.7	1.5-3.1	
ECOG-PS˥  0/1-4	n	325	111	294	730	
	Survival Rate at 3 months	302 (92.9%)	80 (72.1%)	186 (63.3%)	568 (77.8%)	<0.001
	Median Survival 	9.6	5.3	4.2	6.6	
	95% CI	8.4-10.8	4.2-6.6	3.6-5.1	5.8-7.1	
P-value		<0.001	0.021	<0.001	<0.001	
˥ ECOG-P: Eastern Cooperative Oncology Group Performance Status, ˦ mGPS: modified Glasgow Prognostic Score. Statiscial analysis was with χ2 test for linear-by-linear association, or χ2 test for 2 by 2 tables.




Table 45. The relationship between the ECOG-PS, mGPS and 3 month survival rate in patients with a BMI/WL  grade 0/1 and advanced cancer (n=404)
ECOG-PS˥		mGPS˦=0	mGPS˦=1	mGPS˦=2	mGPS˦ 0-2	
		n (%)	n (%)	n (%)	n (%)	P-value
0-1	n	148	32	73	253	
	Survival Rate at 3 months 	144 (97.3%)	26 (81.3%)	62 (84.9%)	232 (91.7%)	0.001
	Median Survival 	11.4	9.4	7.5	9.9	
	95% CI	9.2-14.4	4.0-17.8	6.1-9.9	8.7-11.4	
2	n	49	24	45	118	
	Survival Rate at 3 months 	44 (89.8%)	21 (87.5%)	33 (73.3%)	98 (83.1%)	0.085
	Median Survival 	7.9	6.6	4.9	6.7	
	95% CI	6.8-10.7	5.0-8.9	3.7-6.6	5.2-7.6	
3-4	n	6	5	22	33	
	Survival Rate at 3 months 	4 (66.7%)	3 (60%)	11 (50.0%)	18 (54.5%)	0.741
	Median Survival 	7.2	3.4	2.9	3.2	
	95% CI	1.0-73.2	0.6-8.4	1.2-5.0	1.8-5.0	
ECOG-PS˥  0/1-4	n	203	61	140	404	
	Survival Rate at 3 months	192 (94.6%)	50 (82.0%)	106 (75.7%)	348 (86.1%)	<0.001
	Median Survival 	10.0	7.5	5.7	7.9	
	95% CI	8.9-11.7	5.8-8.9	4.8-7.1	7.3-8.9	
P-value		0.001	0.343	0.003	<0.001	
˥ ECOG-P: Eastern Cooperative Oncology Group Performance Status, ˦ mGPS: modified Glasgow Prognostic Score. Statiscial analysis was with χ2 test for linear-by-linear association, or χ2 test for 2 by 2 tables.







	0 months	6 months 	12 months 	18 months 	24 months 	30 months 	36 months 	42 months
ECOG 0/1	409 	317	236	194	176	166	159	154
ECOG 2	240 	127	95	83	79	74	72	72
ECOG 3/4	81 	22	16	13	12	12	12	12
Figure 1.0:  The relationship between the ECOG-PS and OS in patients with advanced cancer (n=730, Log rank test: ECOG-PS 0/1-2: p<0.001, ECOG-PS 2-3/ 4:p<0.001, ECOG-PS 0/1-3/4: p<0.001)



	0 months	6 months 	12 months 	18 months 	24 months 	30 months 	36 months 	42 months
mGPS 0	325 	270	207	180	166	158	152	150
mGPS 1	111 	66	50	42	41	39	37	35
mGPS 2	294 	130	90	68	61	55	64	53
Figure 2.0:  The relationship between the mGPS and OS in patients with advanced cancer (n=730, Log rank test: mGPS 0-1: p<0.001, mGPS1-2: 0.006, mGPS 0-2: p<0.001)



	0 months	6 months 	12 months 	18 months 	24 months 	30 months 	36 months 	42 months
BMIWLGrade 0/1	404 	300	224	187	171	160	152	148
BMIWLGrade 2/3	241 	131	99	82	77	73	72	71
BMIWLGrade 4	85 	35	24	21	20	19	19	19
Figure 3.0:  The relationship between the BMIWL grade and OS in patients with advanced cancer (n=730, Log rank test: BMIWL grade 0/1-2/3: p<0.001, BMIWL grade 2/3-4: p<0.001, ECOG-PS 0/1-4: p=0.010)
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